

Mark Sullivan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8640653/publications.pdf>

Version: 2024-02-01

14
papers

450
citations

1163117

8
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

780
citing authors

#	ARTICLE	IF	CITATIONS
1	A framework for the development of effective anti-metastatic agents. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 185-204.	27.6	223
2	Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. <i>Science Translational Medicine</i> , 2021, 13, eabd5524.	12.4	62
3	Dimethyl sulfoxide (DMSO) exposure to human peripheral blood mononuclear cells (PBMCs) abolish T cell responses only in high concentrations and following coincubation for more than two hours. <i>Journal of Immunological Methods</i> , 2010, 356, 70-78.	1.4	31
4	A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 [®] in HLA DQ2+ Volunteers With Celiac Disease Following a Long-Term, Strict Gluten-Free Diet. <i>Gastroenterology</i> , 2011, 140, S-437-S-438.	1.3	31
5	Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever. <i>Drug Delivery and Translational Research</i> , 2016, 6, 572-578.	5.8	24
6	The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 386-390.	0.7	20
7	Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis. <i>Journal of Hepatology</i> , 2002, 36, 6-7.	3.7	17
8	Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006837.	3.0	17
9	Moving candidate vaccines into development from research: lessons from HIV. <i>Immunology and Cell Biology</i> , 2009, 87, 366-370.	2.3	7
10	Tenofovir disoproxil fumarate (TDF) suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV. <i>Journal of Hepatology</i> , 2002, 36, 138.	3.7	6
11	Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. <i>Journal of Hepatology</i> , 2002, 36, 138.	3.7	6
12	Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy. <i>Journal of Hepatology</i> , 2002, 36, 7.	3.7	3
13	Non-Immunogenicity of Overlapping Gag Peptides Pulsed on Autologous Cells after Vaccination of HIV Infected Individuals. <i>PLoS ONE</i> , 2013, 8, e74389.	2.5	2
14	Changes in alanine aminotransferase (ALT) and YMDD mutation profile associated with switching from lamivudine (LAM) to either adefovir dipivoxil (ADV) or combination LAM plus ADV in chronic hepatitis B (CHB) patients with LAM resistance. <i>Gastroenterology</i> , 2003, 124, A715.	1.3	1